Cargando…
Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study
BACKGROUND: Efficacy of stereotactic body radiotherapy (SBRT) in stage I non–small-cell lung cancer (NSCLC) has almost been established. In Japan, the protocol of 48 Gy in 4 fractions over 4 days has been most often employed, but higher doses may be necessary to control large tumors. Previously, we...
Autores principales: | Miyakawa, Akifumi, Shibamoto, Yuta, Baba, Fumiya, Manabe, Yoshihiko, Murai, Taro, Sugie, Chikao, Yanagi, Takeshi, Takaoka, Taiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594596/ https://www.ncbi.nlm.nih.gov/pubmed/28893300 http://dx.doi.org/10.1186/s13014-017-0888-7 |
Ejemplares similares
-
Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system
por: Murai, Taro, et al.
Publicado: (2016) -
Changes in pulmonary function and their correlation with dose–volume parameters in patients undergoing stereotactic body radiotherapy for lung cancer
por: Takemoto, Shinya, et al.
Publicado: (2021) -
Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size
por: Baba, Fumiya, et al.
Publicado: (2010) -
Organizing pneumonia after stereotactic ablative radiotherapy of the lung
por: Murai, Taro, et al.
Publicado: (2012) -
Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer
por: Takemoto, Shinya, et al.
Publicado: (2019)